SCHEMBL6284197

SCHEMBL6284197

CC(C)Cc1ccccc1CCC(=O)NS(=O)(=O)CCNC(=O)C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.38
MAPT P10636 1/20 0.37
HPGD P15428 2/20 0.36
ADRB2 P07550 2/20 0.36
ADRB1 P08588 2/20 0.36
MTNR1A P48039 1/20 0.36
MTNR1B P49286 1/20 0.36
LMNA P02545 1/20 0.35
PKM P14618 1/20 0.35
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CYP2C19 P33261 2/20 0.34
PLAAT3 P53816 1/20 0.34
PLAAT5 Q96KN8 1/20 0.34
PLAAT2 Q9NWW9 1/20 0.34
PLAAT4 Q9UL19 1/20 0.34
ANPEP P15144 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6283491 0.83 HTT (0.45) L3MBTL1MAPTLMNASMN1; SMN2
SCHEMBL6283252 0.82 MTNR1A (0.39) MAPTHPGDADRB2ADRB1MTNR1A
SCHEMBL6281738 0.82 RAB9A (0.44) L3MBTL1RAB9ACYP2C19CYP2C9CYP1A2
SCHEMBL6279430 0.81 PTGER1 (0.36) L3MBTL1HPGDLMNAPKMNPC1
SCHEMBL6291899 0.81 SMN1; SMN2 (0.44) MAPTALDH1A1SMN1; SMN2KDM4E
SCHEMBL6284517 0.79 KMT2A (0.47) MAPTLMNAALDH1A1NPC1RAB9A
SCHEMBL3150970 0.72 LMNA (0.46) MAPTHPGDADRB2ADRB1LMNA
SCHEMBL3136623 0.72 MTNR1A (0.45) MAPTHPGDMTNR1AMTNR1BALDH1A1
SCHEMBL3156228 0.71 MAPT (0.57) L3MBTL1MAPTHPGDLMNAALDH1A1
SCHEMBL26741629 0.70 ALDH1A1 (0.48) L3MBTL1MAPTHPGDADRB2ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887903-B1 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them DOMPE S.P.A. (IT) 2005-05-03 US disclosed
US-6881755-B2 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them Dompé S.p.A. (IT) 2005-04-19 US disclosed
US-20030216392-A1 N - ( 2 - aryl - propionyl ) - sulfonamides and pharmaceutical preparations containing them DOMPE S.P.A. 2003-11-20 US disclosed
EP-1123276-B1 N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM DOMPE SPA (IT) 2003-01-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216392-A1 N - ( 2 - aryl - propionyl ) - sulfonamides and pharmaceutical preparations containing them ELANE, MPO, FPR1 L3MBTL1 4579/4885MAPT 4727/4885HPGD 497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.